ArticleValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2017
Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice.
Article in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A blockchain-based framework to support pharmacogenetic data sharing.The pharmacogenomics journal · 2022Pooled it
- Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial.Pharmacogenomics · 2019Trial
- Genetics and Genomics in Sickle Cell Disease in Africa.American journal of hematology · 2026Review
- Trial of Preemptive Pharmacogenetic Testing in Underserved Patients (TOPP UP): Study Framework and Baseline Characteristics of Randomized Controlled Trial Participants.Clinical and translational science · 2026Article
- Patients' Concerns About Receiving Preemptive Pharmacogenomic Testing: Results from a Large, Longitudinal Survey of RIGHT Study Participants.Journal of personalized medicine · 2025Article
- Development of an Ancestrally Inclusive Preemptive Pharmacogenetic Testing Panel.Clinical and translational science · 2025Article
- Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned.Clinical pharmacology and therapeutics · 2024Article
- Pharmacogenomic augmented machine learning in electronic health record alerts: A health system-wide usability survey of clinicians.Clinical and translational science · 2024Article
- Towards genomic medicine: a tailored next-generation sequencing panel for hydroxyurea pharmacogenomics in Tanzania.BMC medical genomics · 2024Article
- Moving towards the implementation of pharmacogenetic testing in Quebec.Frontiers in genetics · 2023Review
- Building Evidence for Clinical Use of Pharmacogenomics and Reimbursement for Testing.Clinics in laboratory medicine · 2022Review
- A Theory-Informed Systematic Review of Barriers and Enablers to Implementing Multi-Drug Pharmacogenomic Testing.Journal of personalized medicine · 2022Review
- Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.Annual review of genomics and human genetics · 2022Review
- Electronic Health Record-Integrated Clinical Decision Support for Clinicians Serving Populations Facing Health Care Disparities: Literature Review.Yearbook of medical informatics · 2022Review
- Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved.Frontiers in genetics · 2022Article
- Approaches to assessing the provider experience with clinical pharmacogenomic information: a scoping review.Genetics in medicine : official journal of the American College of Medical Genetics · 2021Article
- Multi-Institutional Implementation of Clinical Decision Support forJournal of personalized medicine · 2021Article
- Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country.Iranian journal of pharmaceutical research : IJPR · 2021Article
- Public engagement with genomic medicine: a summary of town hall discussions.Journal of community genetics · 2021Article
- The Contribution of Clinical Pharmacologists in Precision Medicine: An Opportunity for Health Care Improvement.Current therapeutic research, clinical and experimental · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesImplementing new programs to support precision medicine in clinical settings is a complex endeavor. We describe challenges and potential solutions based on the Indiana GENomics Implementation: an Opportunity for the Underserved (INGenious) program at Eskenazi Health-one of six sites supported by the Implementing GeNomics In pracTicE network grant of the National Institutes of Health/National Human Genome Research Institute. INGenious is an implementation of a panel of genomic tests.
methodsWe conducted a descriptive case study of the implementation of this pharmacogenomics program, which has a wide scope (14 genes, 27 medications) and a diverse population (patients who often have multiple chronic illnesses, in a large urban safety-net hospital and its outpatient clinics). CHALLENGES: We placed the clinical pharmacogenomics implementation challenges into six categories: patient education and engagement in care decision making; clinician education and changes in standards of care; integration of technology into electronic health record systems; translational and implementation sciences in real-world clinical environments; regulatory and reimbursement considerations, and challenges in measuring outcomes. A cross-cutting theme was the need for careful attention to workflow. Our clinical setting, a safety-net health care system, presented some distinctive challenges. Patients often had multiple chronic illnesses and sometimes were taking more than one pharmacogenomics-relevant medication. Reaching patients for recruitment or follow-up was another challenge.
conclusionsNew, large-scale endeavors in health care are challenging. A description of the challenges that we encountered and the approaches that we adopted to address them may provide insights for those who implement and study innovations in other health care systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.